Results
The demographic data of the patients are given in Table 1. According to the R.E.N.A.L.
nephrometry score, 3 of the patients (8.3%) were medium risk, while the remaining 33
patients (91.7%) were at low risk. 21 (91.3%) of the RFA applications were performed under
the USG guidance, 1 patient was performed under CT guidance (4.3%), RFA was performed
in one patient (4.3%) under laparoscopy using retroperitoneal technique. MWA applications were performed in 2 CT guidance (15.3%) and 11 (84.6%) USG guidance.
3 patients with solitary renal disease who underwent nephrectomy due to renal mass.
The mean duration of ablation was 28.4 ± 5.3 minutes for MWA and 31.9 ± 6.3 for RFA. No
biopsy was performed in 14 patients (42.4%) while 19 (52.7%) of 36 tumors treated with
ablative therapy were biopsied. Pathological evaluation of the entire renal biopsies taken prior
to RFA administration resulted in Clear cell renal cell carcinoma. (CCRCC) In only 2 (6%) of
the cases complications were encountered after ablation. In one patient, acute renal failure and
serum creatinine level were found to be elevated, in the other patient local pain was found in
the ablation loom, and in the USG, minor bleeding was detected at the ablation site.
Recurrence was seen in 7 (30.4%) of the 23 tumors treated with RFA, and 3 (23%) of the
tumors were recurred after MWA application in 13 tumors. Re-RFA was applied to 4 (40%)
of recurrent tumors, MWA to 3 (30%) and targeted therapy at medical oncology clinic to 2
(20%) and active surveillance was applied to 1 (10%). The overall success in MWA
administration was calculated as 76.9%, while the overall success in RFA was 80%. (Table 2)
In the follow-up period, only 1 of our patients is exitus due to illness. The patient who
underwent RFA was previously treated with left radical nephrectomy and right partial
nephrectomy.